Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 11.

Kerr, K M; et al; Bubendorf, L; Stahel, R A (2018). Prevalence and clinical association of gene mutations through Multiplex Mutation Testing in patients with NSCLC: Results from the ETOP Lungscape Project. Annals of Oncology, 29(1):200-208.

Koelzer, V H; Glatz, K; Bubendorf, L; Weber, A; Gaspert, A; Cathomas, G; Lugli, A; Zippelius, A; Kempf, W; Mertz, K D (2017). Pathologie der Nebenwirkungen von Immune-Checkpoint-Inhibitoren. Der Pathologe, 38(3):1-12.

Kerr, K M; Bubendorf, L; Edelman, M J; Marchetti, A; Mok, T; Novello, S; O'Byrne, K; Stahel, R; Peters, S; Felip, E (2014). Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Annals of Oncology, 25(9):1681-1690.

Zappa, F; Droege, C; Betticher, D; von Moos, R; Bubendorf, L; Ochsenbein, A; Gautschi, O; Oppliger Leibundgut, E; Froesch, P; Stahel, R; Hess, T; Rauch, D; Schmid, P; Mayer, M; Crowe, S; Brauchli, P; Ribi, K; Pless, M (2012). Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). Lung Cancer, 78(3):239-244.

Der Pathologe : Organ der Deutschen Abteilung der Internationalen Akademie für Pathologie, der Deutschen, der Österreichischen und der Schweizerischen Gesellschaft für Pathologie und des Berufsverbandes Deutscher Pathologen. Edited by: Baretton, G B; Bubendorf, L; Büttner, R; Feiden, W; Kreipe, H; Kuhnen, C; Lax, S F; Mentzel, T; Moch, H; Saeger, W; Schirmacher, P; Schmidt, D; Schmitt-Gräff, A; Vieth, M; Werner, M; Schmid, K W (2011). Berlin, DE: Springer.

Mengus, C; Le Magnen, C; Trella, E; Yousef, K; Bubendorf, L; Provenzano, M; Bachmann, A; Heberer, M; Spagnoli, G C; Wyler, S (2011). Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer. Journal of Translational Medicine, 9:162.

Savic, S; Franco, N; Grilli, B; Barascud, A V; Herzog, M; Bode, B; Loosli, H; Spieler, P; Schönegg, R; Zlobec, I; Clark, D P; Herman, J G; Bubendorf, L (2010). Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology. Chest, 138(1):137-144.

Zellweger, T; Günther, S; Zlobec, I; Savic, S; Sauter, G; Moch, H; Mattarelli, G; Eichenberger, T; Curschellas, E; Rüfenacht, H; Bachmann, A; Gasser, T C; Mihatsch, M J; Bubendorf, L (2009). Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer. International Journal of Cancer, 124(9):2116-2123.

Savic, S; Zlobec, I; Thalmann, G N; Engeler, D; Schmauss, M; Lehmann, K; Mattarelli, G; Eichenberger, T; Dalquen, P; Spieler, P; Schoenegg, R; Gasser, T C; Sulser, T; Forster, T; Zellweger, T; Casella, R; Bubendorf, L (2009). The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy. International Journal of Cancer, 124(12):2899-2904.

Feder-Mengus, C; Wyler, S; Hudolin, T; Ruszat, R; Bubendorf, L; Chiarugi, A; Pittelli, M; Weber, W; Bachmann, A; Gasser, T C; Sulser, T; Heberer, M; Spagnoli, G C; Provenzano, M (2008). High expression of indoleamine 2,3-dioxygenase gene in prostate cancer. European Journal of Cancer, 44(15):2266-2275.

D'Addario, G; Rauch, D; Stupp, R; Pless, M; Stahel, R; Mach, N; Jost, L; Widmer, L; Tapia, C; Bihl, M; Mayer, M; Ribi, K; Lerch, S; Bubendorf, L; Betticher, D C (2008). Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Annals of Oncology, 19(4):739-745.

This list was generated on Mon Dec 17 11:03:37 2018 CET.